


Technology Appraisal Committee C Interests Register

Topic: Dexamethasone intravitreal implant for treating visual impairment caused by diabetic macular


oedema [ID3951]

Publication Date: 14 September 2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Michael Chambers	Committee Member	Direct - financial	Michael Chambers has participated in an advisory panel for Pfizer in an unrelated disease area (prostate cancer) and has helped co-ordinate a (University of Utrecht) training programme in Real World Evidence for Roche, which did not involve consideration of any Roche products. Both Pfizer and Roche are manufacturers of possible comparator therapies.	-	05/07/2022	-	It was agreed his declaration would not prevent Michael from participating in discussions on this appraisal.
Dr Richard Nicholas	Committee Member	Direct - financial	Dr Richard Nicholas has carried out paid advisory boards with Roche and Novartis in an unrelated area - multiple sclerosis.	-	05/07/2022	-	It was agreed his declaration would not prevent Michael from participating in discussions on this appraisal.



Professor Winfried Amoaku	Clinical expert	Direct financial and non-financial interests	Professor Winfried Amoaku declared the following: - His institution has received funding for research he has participated in sponsored by Allergan, Bausch and Lomb, Novartis, Pfizer, and Roche.	-	11/11/2021		It was agreed his declaration would not prevent Professor Amoaku from providing expert advice to the committee.
			- He has served on advisory boards and received honoraria from Abbvie, Alcon, Allergan, Bayer, Novartis, Pfizer, Roche, Apellis, Biogen, and Teva Pharma				
			 He has advised Roche on current and potential future Treatment Pathways for Geographic Atrophy. 				
			 He has received Educational Travel Grants from Alimera, Allergan, Bayer, Novartis, and Pfizer. 				
			 He is a member of the Data & Safety Monitoring Board, and several Trial Steering Committees. 				
Professor Faruque Ghanchi	Clinical expert	Direct financial and non- financial interests	Professor Faruque Ghanchi has provided consultancy work for Abbvie/Allergan, Alimera(past), Novartis and Roche, and he has an academic interest in diabetic	-	05/07/2022	-	It was agreed his declaration would not prevent Professor Ghanchi from providing



			retinopathy, involved in clinical research on new therapeutic agents.				expert advice to the committee.
Stephen Scowcroft	Patient expert	Indirect financial	Stephen Scowcroft declared indirect financial interests as Macular Society receive financial support from a variety of pharma companies, none have any direct editorial input into our information/activities.	-	15/11/2021	-	It was agreed his declaration would not prevent Stephen from providing expert advice to the committee